Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects

Fig. 3

Nb36 promoted DC-CIK cell proliferation and eliminated target cells. A CFSE-labeled DC-CIK cells were mixed with different antibodies and co-cultured for 120 h. DC-CIKcell proliferation was assessed via flow cytometry. B Quantitative analysis of proliferation frequency of DC-CIK cells. n = 3, *P < 0.05, *** P < 0.001. C Expansion folds of DC-CIK cells stimulated with HepG2. n = 3. D and E DC-CIK cells were co-incubated with the indicated cells, and labeled with PKH26 at the E/T ratios of 5:1, 10:1 and 20:1 for 6 h. The ratios of PHK26+PI+ were measured by flow cytometry. Nb36-treated DC-CIK cells had enhanced cytotoxicity against HepG2 and A549 target cells. n = 3.FlowJo v10.07 software was utilized for statistical analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us